Mattia Galli/LinkedIn
Nov 12, 2025, 05:16
Mattia Galli on The Choice in ASCVD: Aspirin or P2Y12 Inhibitor Monotherapy?
Mattia Galli, Assistant Professor at Sapienza University of Rome, Associate Editor of European Heart Journal, shared on LinkedIn:
”Should P2Y12 inhibitor be preferred over aspirin for long treatment in ASCVD patients?
All you need to know in this balanced, yet comprehensive State-of-the-Art review published in the European Heart Journal.”
Read the full article in EHJ.
Article: Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?
Authors: Mattia Galli, Jurrien ten Berg, Marco Valgimigli, Davide Capodanno, Felice Gragnano, Takeshi Kimura, Deepak L Bhatt, C Michael Gibson, Roxana Mehran, Dominick J Angiolillo
Stay updated on all scientific advances with Hemostasis Today.
-
Dec 15, 2025, 15:58Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
-
Dec 15, 2025, 12:46Deborah Ebert Long on Hemophilia Care: Progress, Possibility, and the Power of Listening
-
Dec 15, 2025, 12:34Nathan Connell on Conversion from Eptacog Alfa to Beta
-
Dec 15, 2025, 12:17Danny Hsu on Interdisciplinary Toolkit for Gynecologic Bleeding on Anticoagulation
-
Dec 15, 2025, 12:08Ted Roh: A Historic Milestone for Indonesia’s Health Innovation
-
Dec 15, 2025, 11:28Wolfgang Miesbach Shares Insights from Davide Matino’s Presentation on Marstacimab at ASH25
-
Dec 15, 2025, 11:12Tushar Pandey Awarded for His Enourmous Contribution to Hematology
-
Dec 15, 2025, 11:07DISTRO: Vidya Rajbhoj on AI and Digital Technology to Improve Stroke Rehabilitation
-
Dec 15, 2025, 11:00Ischemic Stroke, AF and Atherosclerotis: Amira Khater on Sufficiency of Anticoagulant Monotherapy